Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients

Br J Cancer. 2003 May 19;88(10):1570-7. doi: 10.1038/sj.bjc.6600918.

Abstract

In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2((c))), and for a randomly selected sample of 3.4% women with negative findings on both. Quality control included reviews of cytology, histology, colposcopy images and retesting of samples with polymerase chain reaction. Test diagnostic performances were based on 7908 women who had complete baseline and follow-up results. Routine histology identified 86 women with high-grade cervical intraepithelial neoplasia (CIN2+), which was confirmed by review histology in only 46 cases. Sensitivity of routine cytology for the detection of CIN2+ was 43.5%, with a specificity, positive predictive value (PPV), negative predictive value (NPV) of 98.0, 11.4 and 99.7%, respectively. Sensitivity of the HC2 test for the detection of CIN2+ was 97.8%, with a specificity, PPV and NPV, of 95.3, 10.9 and 100%, respectively. No high-grade neoplasia was detected in the randomly selected control group. A negative HPV-test result, even in combination with a positive Papanicolaou (Pap) result, virtually excluded any risk of underlying high-grade disease, but this was not the case for a negative Pap result. These data show that HPV testing is of value for the detection or exclusion of prevalent CIN in a routine cervical cancer-screening setting and could be used for further risk classification of women for follow-up management.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cohort Studies
  • Colposcopy
  • DNA Primers
  • DNA, Viral / analysis
  • Female
  • Germany
  • Humans
  • Mass Screening*
  • Middle Aged
  • Papanicolaou Test*
  • Papillomaviridae / pathogenicity*
  • Papillomavirus Infections / diagnosis*
  • Polymerase Chain Reaction
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Prospective Studies
  • Quality Control
  • Risk Assessment
  • Sensitivity and Specificity
  • Tumor Virus Infections / diagnosis*
  • Uterine Cervical Neoplasms / diagnosis
  • Uterine Cervical Neoplasms / etiology
  • Uterine Cervical Neoplasms / virology*
  • Vaginal Smears*

Substances

  • DNA Primers
  • DNA, Viral